FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Subscribe To Our Newsletter & Stay Updated